Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists by Percie du Sert, N. et al.
Cancer Chemother Pharmacol (2011) 67:667–686
DOI 10.1007/s00280-010-1339-4
123
ORIGINAL ARTICLE
Cisplatin-induced emesis: systematic review and meta-analysis 
of the ferret model and the eVects of 5-HT3 receptor antagonists
N. Percie du Sert · J. A. Rudd · C. C. Apfel · 
P. L. R. Andrews 
Received: 22 March 2010 / Accepted: 16 April 2010 / Published online: 28 May 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose The ferret cisplatin emesis model has been used
for »30 years and enabled identiWcation of clinically used
anti-emetics. We provide an objective assessment of this
model including eYcacy of 5-HT3 receptor antagonists to
assess its translational validity.
Methods A systematic review identiWed available evi-
dence and was used to perform meta-analyses.
Results Of 182 potentially relevant publications, 115
reported cisplatin-induced emesis in ferrets and 68 were
included in the analysis. The majority (n = 53) used a
10 mg kg¡1 dose to induce acute emesis, which peaked
after 2 h. More recent studies (n = 11) also used 5 mg kg¡1,
which induced a biphasic response peaking at 12 h and
48 h. Overall, 5-HT3 receptor antagonists reduced cisplatin
(5 mg kg¡1) emesis by 68% (45–91%) during the acute
phase (day 1) and by 67% (48–86%) and 53% (38–68%,
all P < 0.001), during the delayed phase (days 2, 3). In an
analysis focused on the acute phase, the eYcacy of ondan-
setron was dependent on the dosage and observation period
but not on the dose of cisplatin.
Conclusion Our analysis enabled novel Wndings to be
extracted from the literature including factors which may
impact on the applicability of preclinical results to humans.
It reveals that the eYcacy of ondansetron is similar against
low and high doses of cisplatin. Additionally, we showed
that 5-HT3 receptor antagonists have a similar eYcacy
during acute and delayed emesis, which provides a novel
insight into the pharmacology of delayed emesis in the
ferret.
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Abbreviations
5-HT3 5-Hydroxytryptamine3
NK1 Neurokinin1
i.v. Intravenous
i.p. Intraperitoneal
p.o. Per os, oral
s.c. Sub-cutaneous
R+V Retches and vomits
SD Standard deviation
CI ConWdence interval
Introduction
It is generally accepted that nausea and vomiting (emesis)
are components of a protective mechanism by which the
human body defends itself against ingested toxins. How-
ever, the emetic reXex can be triggered inappropriately, and
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nausea and vomiting are also relatively common side
eVects of drugs in current use (e.g. morphine, anti-cancer
chemotherapy) as well as dose-limiting toxicities, which
may limit the development of novel chemical entities
intended for the treatment of a range of diseases (e.g. phos-
phodiesterase-IV inhibitors for the treatment of asthma
[135]). The multi-system nature of the emetic reXex coordi-
nated in the brainstem and the behavioural and sensory
expression of nausea have meant that, to date, preclinical
studies of the mechanisms involved and identiWcation of
novel anti-emetic agents have involved studies in whole
animals (conscious, anaesthetised or decerebrate) [61].
Nausea and vomiting are particularly associated with the
treatment of cancer by cytotoxic drugs (e.g. cisplatin),
symptoms which patients Wnd particularly distressing and
impact upon compliance with treatment. In the absence of
anti-emetic prophylaxis, cisplatin induces nausea and vom-
iting in virtually all patients [109]; the emetic response lasts
up to 5 days on each cycle and is characterised by an
intense acute phase lasting »24 h and a less intense but
more protracted delayed phase peaking during the period
48–72 h following the administration of cisplatin [72]. In
the early 1980s, the ferret (Mustela putorius furo L.) was
reported to develop an acute emetic response to high-dose
cisplatin (8–10 mg kg¡1) and was proposed as an alterna-
tive model to the dog, cat and monkey (commonly used at
the time) to study cytotoxic drug-induced emesis and iden-
tify potential anti-emetic agents [40]. Subsequently, the
acute cisplatin model was modiWed and the dose of cis-
platin lowered to 5 mg kg¡1 to investigate delayed emesis
[114]. The ferret model of cisplatin-induced emesis was
rapidly adopted for the investigation of new anti-emetic
agents and was pivotal in establishing the anti-emetic
eYcacy of 5-hydroxytryptamine3 (5-HT3) [94] and tachykinin
NK1 receptor antagonists [148], which are both currently in
widespread use for the treatment of chemotherapy-induced
nausea and vomiting [109].
The use and beneWt of animal models in research is regu-
larly questioned and anecdotal evidence or unsupported
claims, as opposed to quantitative support, are too often
used as justiWcations [88, 105]. There has recently been a
growing interest in systematic reviews and meta-analyses
to assess the validity of animal models (i.e. how preclinical
research has informed clinical research) and their utility in
drug discovery (i.e. evaluate data and inform the decision
to carry out a clinical trial). The NuYeld Council for
Bioethics [101] recommends that such reviews are under-
taken to “evaluate more fully the predictability and trans-
ferability of animal models”. Such analyses also have
implications for the application of the principles of the 3Rs
(Replacement, ReWnement, Reduction) to animal experi-
mentation [61, 68] and should inform preclinical guidelines
produced by regulators (e.g. [37]). Recently, systematic
reviews and meta-analysis of animal models of stroke have
been carried out. A retrospective study concluded that even
though individual studies had reported beneWcial eVects of
the calcium channel blocker nimodipine; overall, the pre-
clinical data available were not conclusive [62], which is
consistent with the fact that this type of drug was without
eVect in humans [63] and highlights the necessity of quanti-
fying animal data adequately before starting clinical trials.
Later studies assessed the preclinical evidence of the eVect
of potential treatments in experimental stroke and charac-
terised their neuroprotective properties in order to identify
research priorities [78–80].
The cisplatin-induced emesis ferret models provide a
unique opportunity to assess the value of systematic reviews
in speciWc areas, because the wealth of data available in this
relatively circumscribed area allows assessment of two char-
acteristics of a model: the response to cisplatin itself, and the
anti-emetic potential of agents that are currently used in
humans. The aim of this systematic review is twofold:
Wrstly, this study intends to provide an objective measure of
the characteristics of cisplatin-induced emesis in the ferret,
in terms of the latency, magnitude (number of retches and
vomits) and proWle of the emetic response. Secondly, the
eVect of 5-HT3 receptor antagonists in the ferret model will
be quantiWed; the present study will assess the eYcacy of
ondansetron against the acute phase of emesis; additionally,
we will compare the overall eVect of 5-HT3 receptors antag-
onists against the acute and delayed phases of emesis.
This paper is the Wrst systematic review and meta-analysis
covering a model of emesis and anti-emetics. It provides
evidence, which supports the predictability of the model
and identiWes new features of the model not apparent from
individual studies. Additionally, it shows the limitations of
the model and identiWes opportunities for enhanced animal
welfare according to the principles of the “3Rs” formulated
by Russell and Burch over 50 years ago [126].
Methods
Search strategy
Studies were identiWed from Pubmed (1974 to March 2007)
and Embase (1980 to March 2007) using the combination
of words: CISPLATIN and FERRET; hand searching of
abstracts of scientiWc meetings and personal Wles. All refer-
ences of newly identiWed publications were also screened
until no further eligible references were found. Language
was not restricted. Values for data expressed graphically
were either requested from authors or measured from the
graphs. Corresponding authors were also contacted to
obtain data that was not reported clearly enough in their
publications.Cancer Chemother Pharmacol (2011) 67:667–686 669
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Inclusion criteria:
• Report of cisplatin-induced emesis in the ferret
• Emetic response documented, and quantiWed by at least
one of the following: latency to onset of emesis (retching
or vomiting), number of animals developing emesis,
number of retches (R), vomits (V), retches and vomits
(R+V) deWned according to our deWnition and reported
as mean only or mean § SEM or SD, and number of fer-
rets per group.
Exclusion criteria:
• Number of animals not stated
• Emetic response investigated under anaesthesia
• Emetic response not reported as the number of animals
developing emesis, or mean latency, or mean number of
retches and vomits compatible with the standard deWni-
tion of emesis.
Emesis was deWned as retching (i.e. rhythmic abdominal
contractions against a closed glottis) and vomiting (i.e.
rhythmic abdominal contractions associated with the
oral expulsion of solid or liquid materials from the gas-
trointestinal tract) [14, 22, 89]. Reports stating this deW-
nition in their methods section were included in this
study; if the deWnition was absent or unclear, evaluation
of the results reported and their inclusion in this quanti-
tative review were left to the judgement of the investiga-
tor and discussed with co-workers; reports were
included:
• If the same team had published other reports clearly stat-
ing this deWnition or a member of the team—most senior
or corresponding author—was contacted to conWrm the
deWnition used to characterise emesis
• If the report referred to publications clearly stating this
deWnition
• If the deWnition stated allowed the identiWcation of the
number of retches and/or vomits according to our deWni-
tion.
The latency (time to onset of emesis) was a potential con-
founding factor as many publications reported the latency
as a mean for all the animals in the groups, including those
free of emesis, in which case the latency was taken as the
total duration of the observation time. All latencies were
recalculated as the mean latency to the Wrst retch or vomit
in animals that developed emesis only. The latency was
either measured as the time to the Wrst retch, the time to the
Wrst vomit or the time to the Wrst emetic episode. All the
latencies reported were included combined together, as it
was considered that only a minimal period of time separates
the  Wrst retch from the Wrst vomit [144], a more rigid
approach including only the studies with either one or the
other measurement and excluding those reporting the
latency to the Wrst emesis or emetic episode would have
induced a greater error.
Data extraction and analysis
Meta-analysis: the ferret model of cisplatin-induced emesis
The number of retches (R), vomits (V), retches + vomits
(R+V) and/or latency data from control groups (i.e. animals
that received no other drug than cisplatin or cisplatin and an
inactive—i.e. non-emetogenic—vehicle) were extracted as
mean, standard deviations (SD) and number of animals per
group. Weighted mean and weighted mean of the SD were
calculated and a one-way ANOVA was carried out to com-
pare the onset of emesis following diVerent doses of cis-
platin. Unless stated, all results are reported as mean § SD.
In order to identify variables modulating the emetic
response, subgroup analyses were carried out according to
criteria such as the vehicle used, duration of the observation
period, the mode of administration of cisplatin (i.v. or i.p.),
the use of anaesthesia and the recovery time prior to the
emetic challenge, the strain (Wtch or albino), sex and origin
of the ferrets. This analysis was only carried out on the
most common doses of cisplatin used to induce acute
(10 mg kg¡1) and acute and delayed emesis in the ferret
(5 mg kg¡1); the two doses were treated separately.
Weighted means and the weighted mean of the SDs were
calculated and proWles of emesis were constructed with
Graphpad Prism® version 5.0, Graphpad Software Inc., San
Diego, USA. DiVerences were assessed by a one-way anal-
ysis of variance (ANOVA) or independent sample t tests as
appropriate. Descriptive statistics and comparisons were
carried out using SPSS® 14.00, SPSS Inc., Chicago, USA
and CLINSTAT (M. Bland). DiVerences were considered
statistically signiWcant when P <0 . 0 5 .
Meta-analysis: the eVect of anti-emetics
For the meta-analysis of the eVects of anti-emetics, compar-
isons were only included if the eVect of a prophylactic anti-
emetic treatment was reported, the 3 outcomes measured
were: the number of R+V, proportion of animals experienc-
ing emesis and latency to the onset of emesis. To calculate
the eVect size and its 95% conWdence interval for the con-
tinuous outcomes (i.e. R+V and latency), the mean out-
come for the treatment group, and the SDs in treatment and
control groups were expressed as a proportion of the out-
come in the control group [80]. Actual data were used for
dichotomous outcomes (i.e. the number of animals with
emesis). When a control group was used to assess more
than one treatment group, the number of animals in the con-
trol group was divided by the number of treatment groups
and if needed, adjusted to the next integer. This methodology670 Cancer Chemother Pharmacol (2011) 67:667–686
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is consistent with what has been done in another meta-
analysis of animal data in a model of stroke [80]. The eVect
of ondansetron was examined for each of the 3 outcomes;
subgroup analyses were carried out depending on the dose
of cisplatin and duration of the observation period, dose,
timing and mode of administration of ondansetron, mode of
administration of cisplatin, origin of the ferrets, and quality
score of the study. Additional analyses examined the eVects
of 5-HT3 receptor antagonists on the latency to the onset of
cisplatin (10 mg kg¡1)-induced emesis and on the acute and
delayed R+V induced by 5 mg kg¡1 cisplatin (criteria for
variation: individual compound). In the later analysis, com-
parisons on a given day were only included if the anti-
emetic treatment started before or at the start of the 24-h
period and was continued throughout the day.
Methodological quality of individual studies was
assessed according to criteria chosen to evaluate the reli-
ability of the data extracted. These criteria were: no dupli-
cate publication identiWed—conWrmed or suspected—,
retch and vomit clearly deWned or deWnition conWrmed by
authors, latency to the Wrst retch or vomit given, SEM/SD
given for the mean latency, number of retches and vomits
or R+V given, SEM/SD given for the mean R+V, number
of ferrets completely protected given (1 point per criterion
fulWlled), origin, sex, strain and body weight of the ferrets
given (1/2 point per criterion fulWlled). Each study was
given a quality score out of a possible total of 9 points. The
DerSimonian and Laird method was used to combine
dichotomous (risk diVerence [RD]) and continuous data
(weighted mean diVerence [WMD]). The random-eVects
model was chosen over the Wxed eVect assumption because
it incorporates inter-study diVerences into the analysis of
the overall treatment eYcacy [28]. The data were analysed
with Review Manager (RevMan. Version 5.0 for Macin-
tosh. Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2008). All eVect estimates are
reported as mean and 95% conWdence intervals. Z tests
were used to assess the overall eVect of treatments and Chi-
squared (2) tests were used to assess the heterogeneity
along with I2, which describes the percentage of the vari-
ability in eVect estimates that is due to heterogeneity rather
than chance (a value greater than 50% may be considered
substantial heterogeneity). The diVerences between the
treatment eVects of sub-categories of a particular outcome
were assessed by a Z test [1,  87], potential publication
biases were assessed by Funnel plots [143].
Anti-emetic drugs examined
Ondansetron: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-
2,3-dihydro-1H-carbazol-4-one. Granisetron: 1-methyl-N-
(9-methyl-9-azabicyclo[3.3.1]nonan-7-yl)indazole-3-car-
boxamide. Indisetron: N-(3,9-dimethyl-3,9-diazabicy-
clo[3.3.1]nonan-7-yl)-1H-indazole-3-carboxamide.
Zacopride: 4-amino-N-(1-azabicyclo[2.2.2]octan-8-yl)-5-
chloro-2-methoxybenzamide. FK1052: (7S)-10-methyl-7-
[(5-methyl-1H-imidazol-4-yl)methyl]-8,9-dihydro-7H-pyr-
ido[1,2-a]indol-6-one hydrochloride. Dolasetron: (3R)-10-
oxo-8-azatricyclo[5.3.1.03,8]undec-5-yl 1H-indole-3-car-
boxylate. L-683,877: 21-(1-Methyl-lH-indol-3-yl)-)spiro(1-
azabicyclo[2.2.2]octane-3,51 (41H)-oxazole. Ramosetron:
(1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimi-
dazol-5-yl]methanone. Azasetron: N-(1-azabicy-
clo[2.2.2]octan-8-yl)-6-chloro-4-methyl-3-oxo-1,4-
benzoxazine-8-carboxamide. Renzapride: 4-amino-N-
[(5S,6S)-1-azabicyclo[3.3.1]nonan-6-yl]-5-chloro-2-meth-
oxybenzamide. Bemesetron: [(1S,5R)-8-methyl-8-azabicy-
clo[3.2.1]octan-3-yl] 3,5-dichlorobenzoate.
Results
Publications
As of March 2007, 182 publications were retrieved, 115
publications describing cisplatin-induced emesis in the fer-
ret were identiWed, 32 publications were excluded and 83
publication contained usable data (Fig. 1; Tables 1, 2). A
further 15 publications were excluded on the grounds that
data was already reported elsewhere. The remaining 68
publications were either fully or partly included as some
papers presented original data and duplicate data together,
in this case only the original data was extracted and the
duplicate data was ignored.
Out of the 68 publications from which at least one out-
come was extracted, 44, 10 and 9 publications reported the
eVect of at least one 5-HT3, NK1 receptor antagonist and
Fig. 1 Flow chart of identiWed studies. Reproduced and adapted from
the QUOROM statement Xow diagram [97]Cancer Chemother Pharmacol (2011) 67:667–686 671
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glucocorticoid, respectively. In terms of outcome, 63 stud-
ies reported the latency, which was either measured as the
latency to the Wrst retch (13% of the publications reporting
the latency), the latency to the Wrst vomit (16%) or the
latency to the Wrst emetic episode (75%). Fifty-one studies
reported the number of retches and vomits (R+V) in a given
observation time, 37 and 36 studies respectively reported
the number of retches and vomits separately. The number
of animals with emesis during the duration of the observa-
tion time was reported in 45 publications.
Table 1 List of 68 included publications
For each included study, the quality score (out of 9), the dose and mode of administration of cisplatin and the duration of the acute phase observa-
tion period are indicated
Study Quality 
score
Cisplatin dose Obs. 
period
Study Quality 
score
Cisplatin dose Obs. 
period
Angel et al. (1993) [4] 7 10 mg kg¡1, i.v. 3 h Minami et al. (1998) [91]6 1 0 m g k g ¡1, i.p. 6 h
Barnes et al. (1987) [6] 6 10 mg kg¡1, i.v. 4 h Miner et al. (1986a) [94]4 1 0 m g k g ¡1, i.v. 4 h
Barnes et al. (1988) [5] 9 10 mg kg¡1, i.v. 3 h Miner et al. (1987) [96]4 1 0 m g k g ¡1, i.v. 4 h
Barnes et al. (1991) [7] 7 10 mg kg¡1, i.v. 4 h Nakayama et al. (2005) [99] 8.5 5, 10 mg kg¡1, i.p. 24, 4 h
Bermudez et al. (1988) [9] 4.5 10 mg kg¡1, i.v. 4 h Ozaki and Sakamoto (1999) [103]7 1 0 m g k g ¡1, i.v. 4 h
Bingham et al. (1994) [11] 4.5 12.5 mg kg¡1, i.v. 4 h Reynolds et al. (1991) [108]6 1 0 m g k g ¡1, i.p. 3 h
Blower (1990) [12] 6 10 mg kg¡1, i.v. 4 h Rudd et al. (1992) [111]5 1 0 m g k g ¡1, i.v 4 h
Costall et al. (1986) [21] 7 10 mg kg¡1, i.v. 2 h Rudd et al. (1994a) [114]6 . 5 1 0 m g k g ¡1, i.p. 40 h
Costall et al. (1987b) [19] 6 10 mg kg¡1, i.v. 2 h Rudd and Naylor (1994b) [117] 5 5, 10 mg kg¡1, i.p. 24 h
Costall et al. (1987c) [22] 6.5 10, 15 mg kg¡1, i.v. 2 h Rudd and Naylor (1994c) [118]6 1 0 m g k g ¡1, i.v. 4 h
Costall et al. (1990a) [20] 7 10, 15 mg kg¡1, i.v. 4 h Rudd et al. (1996b) [115] 7.5 5, 10 mg kg¡1, i.p. 24, 40 h
Costall et al. (1990b) [23] 7 10 mg kg¡1, i.v. 4 h Rudd and Naylor (1996c) [119] 7 . 5 5m gk g ¡1, i.p. 24 h
Davis (1988) [26] 8 10, 12, 20
mg kg¡1, i.v.
2 h Rudd et al. (1996a) [112]8 1 0 m g k g ¡1, i.v. 4 h
Delagrange et al. (1996) 
[26, 27]
3 . 5 1 0m gk g ¡1, i.p. 5 h Rudd and Naylor (1997) [120]8 . 5 1 0 m g k g ¡1, i.p. 24 h
Endo et al. (1990b) [33] 6 7, 10 mg kg¡1, i.p. 6 h Rudd et al. (1998b) [113]5 . 5 1 0 m g k g ¡1, i.p. 24 h
Endo et al. (1994) [36] 6.5 10 mg kg¡1, i.p. 6 h Rudd et al. (2006a) [122]6 1 0 m g k g ¡1, i.p. 6 h
Fink-Jensen (1992) [38] 5 10 mg kg¡1, i.v. 4 h Rycroft et al. (1996) [127]5 1 0 m g k g ¡1, i.v. 4 h
Florczyk et al. (1982) [40] 5 6, 8, 10
mg kg¡1, i.v.
4 h Sam et al. (2001) [128] 7 . 5 5m gk g ¡1, i.p. 24 h
Fukunaka et al. (1998) [42]8 5 m g k g ¡1, i.p. 24 h Sam et al. (2003) [129] 7 . 5 5m gk g ¡1, i.p. 24 h
Gonsalves et al. (1996) [47] 7.5 10 mg kg¡1, i.p. 2 h Sam et al. (2007) [130] 7 . 5 5m gk g ¡1, i.p. 24 h
Gylys et al. (1988) [49] 5 12 mg kg¡1, i.v. 4 h Schurig et al. (1982) [131] 5 . 5 8m gk g ¡1, i.p. 4 h
Haga et al. (1993) [50]4 . 5 8 m g k g ¡1, i.v. 5 h Shiroshita et al. (1993) [132]6 1 0 m g k g ¡1, i.p. 6 h
Hawthorn et al. (1988) [56] 8.5 10 mg kg¡1, i.p. 4 h Singh et al. (1997) [134] 4 . 5 5m gk g ¡1, i.p. 24 h
Higgins et al. (1989) [59]5 . 5 9 m g k g ¡1, i.p. 3 h Taniguchi et al. (2004) [137] 5 5m gk g ¡1, i.p. 24 h
Kamato et al. (1991) [67] 6.5 10 mg kg¡1, 
i.v., i.p.
4 h Tattersall et al. (1992) [139]7 . 5 1 0 m g k g ¡1, i.v. 4 h
Kamato et al. (1993) [66] 6.5 10 mg kg¡1, i.v. 6 h Tattersall et al. (1993) [142]5 . 5 1 0 m g k g ¡1, i.v. 4 h
King and Sanger (2005) [70] 7.5 10 mg kg¡1, i.p. 6 h Tattersall et al. (2000) [140] 3.5 5, 10 mg kg¡1,
i.p., i.v.
24, 4 h
Lau et al. (2005) [75] 7.5 10 mg kg¡1, i.p. 2 h Tsuchiya et al. (2002) [144] 7 . 5 5m gk g ¡1, i.p. 24 h
Lehmann and Karrberg 
(1996) [76]
7 . 5 1 0m gk g ¡1, i.v. 3 h Watson et al. (1995) [148] { 7 . 5 1 0m gk g ¡1, i.p. 2 h
Marr et al. (1992) [81] 6.5 10 mg kg¡1, i.v. 4 h Yamakuni et al. (2002) [150] 5 5, 10 mg kg¡1, i.p. 24, 4 h
Marr et al. (1994a) [82] 7 10 mg kg¡1, i.v. 4 h Yamakuni et al. (2006) [149] 7.5 5, 10 mg kg¡1, 
i.p., i.v.
24, 4 h
Marr et al. (1994b) [83] 3.5 12.5 mg kg¡1, i.v. 4 h Yoshida et al. (1992a) [151]4 1 0 m g k g ¡1, i.v. 3 h
Miller et al. (1993) [90] 7 10 mg kg¡1, i.v. 4 h Yoshida et al. (1993) [153]4 . 5 1 0 m g k g ¡1, i.v. 3 h
Minami et al. (1997) [93] 6 10 mg kg¡1, i.p. 6 h Yoshikawa et al. (2001b) [157]3 . 5 1 0 m g k g ¡1, i.v. 4 h672 Cancer Chemother Pharmacol (2011) 67:667–686
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Meta-analysis: the ferret model of cisplatin induced emesis
Dose of cisplatin
The latency to the onset of emesis was dose dependant; the
time of onset was signiWcantly delayed following a dose of
cisplatin of 5 mg kg¡1, compared with higher doses (6–
20 mg kg¡1, one-way ANOVA followed by Bonferroni
post-tests, see Fig. 2). Additionally, diVerences between the
doses of 6–20 mg kg¡1 were detected (P < 0.001, one way
ANOVA) and the latency shortened when the dose
increased.
The 10 mg kg¡1 cisplatin model
The duration of the observation period varied from 2 to
40 h (at which time the animals were killed). The most
common observation period was 4 h, during which
107 § 48 R+V (n = 199, 22 studies) were observed. In
studies using 2, 3, 6, 24 and 40 h observation periods,
79 § 35 R+V (n = 40, 6 studies), 101 § 48 R+V (n =2 9 ,  3
studies), 170 § 56 R+V (n = 73, 8 studies), 204 § 52 R+V
(n = 16, 3 studies) and 188 R+V (n = 4, 1 study) were
observed, respectively. The number of R+V signiWcantly
increased as the observation period increased up to 24 h
(one-way ANOVA, P < 0.001). The intensity of emesis
reached a maximum after 2 h and decreased to a very low
level (less that 5 R+V per hour) from 3 h onward post cis-
platin (Fig. 3a).
The latency to the onset of emesis was shorter when cis-
platin was administered intravenously (1.16 § 0.35 h,
n = 277) compared to intraperitoneally (1.51 § 0.29 h,
n = 134, P < 0.001, independent sample t test). However,
the route of administration was directly related to the use of
anaesthesia, and all the animals injected with cisplatin
Table 2 List of 47 excluded publications
Reason for exclusion is indicated as: duplicate: data published elsewhere; group number: number of animals in the group missing; emesis: emesis
not quantiWed as number of animals free of emesis, number of retches, number of vomits or latency, or emesis not deWned; anaesthesia: emetic
response investigated in anaesthetized animals
Study Reason for 
exclusion
Study Reason for 
exclusion
Study Reason for 
exclusion
Blum et al. (1992) [13] Emesis Gooch et al. (1998) [48] Anaesthesia Rudd et al. (2001) [116] Group number
Bountra et al. (1993) [15] Emesis Haga et al. (2000) [51] Emesis Rudd et al. (2006b) [123] Duplicate
Chevalier et al. (1998) [16] Emesis Hale et al. (1998) [53] Duplicate Rupniak et al. (1997) [125]E m e s i s
Clark et al. (1993) [17] Duplicate Hale et al. (2000) [52] Duplicate Shiroshita et al. (1992) [133]E m e s i s
Costall et al. (1987a) [18] Duplicate Hargreaves et al. (1994) [54] Duplicate Stables et al. (1987) [136] Duplicate
Eglen et al. (1993) [31] Emesis Hollingworth et al. (2006) [60] Group number Tattersall et al. (1990) [138] Duplicate
Eglen et al. (1994) [29] Emesis Ito et al. (1990) [64] Emesis Tattersall et al. (1996) [141] Group number
Eglen et al. (1995) [30] Emesis Kim et al. (2005) [69] Emesis Twissell et al. (1993) [145] Duplicate
Endo et al. (1990a) [32] Duplicate Lasheras et al. (1996) [74] Emesis Van Sickle et al. (2003) [146]E m e s i s
Endo et al. (1992) [34] Group number Matsui et al. (1992) [86] Emesis Yoshida et al. (1991) [154]E m e s i s
Endo et al. (1995) [35] Emesis Minami et al. (1991) [92] Duplicate Yoshida et al. (1992b) [152]E m e s i s
Fitzpatrick et al. (1990) [39] Emesis Miner et al. (1986b) [95] Duplicate Yoshikawa et al. (1996) [155]E m e s i s
Florczyk et al. (1981) [41] Duplicate Monkovic et al. (1988) [98] Emesis Yoshikawa et al. (2001a) [156]E m e s i s
Gardner et al. (1994) [45] Emesis Ohta et al. (1996) [102] Emesis Youssefyeh et al. (1992a) [159] Duplicate
Gardner et al. (1995) [46] Emesis Price et al. (1990) [107] Emesis Youssefyeh et al. (1992b) [158] Duplicate
Gardner et al. (1996) [44] Emesis Rudd et al. (1998a) [121]E m e s i s
Fig. 2 Latency to the onset of emesis (Wrst retch, vomit or vomiting
episode) induced by various doses of cisplatin. Data collected from 64
studies involving 702 animals and plotted on the graph as weighted
mean § SD. DiVerences between the doses were assessed by one-way
ANOVA followed by Bonferroni post-tests, ***p < 0.0001 compared
with all other doses in the post-tests. The exact latency values, the
number of ferrets from which those values were calculated (n) and the
number of studies from which this data was extracted (S) are given
above each columnCancer Chemother Pharmacol (2011) 67:667–686 673
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intravenously (i.v.) had prior anaesthesia during which an
i.v. line was implanted or were anaesthetised at the time of
cisplatin injection, and prior anaesthesia was not reported in
any of the animals that received an intraperitoneal (i.p.)
injection of cisplatin. The recovery period between anaes-
thesia and the administration of cisplatin did not make a
diVerence as ferrets that received cisplatin under anaesthe-
sia developed emesis with a latency of 1.21 § 0.32 h
(n = 93), and those allowed up to 3 and more than 3 days
recovery developed emesis with a latency of 1.11 § 0.31 h
(n = 51) and 1.13 § 0.46 h (n = 89), respectively (one-way
ANOVA, P = 0.21). The use of an injectable anaesthetic
(sodium pentobarbital 30–35 mg kg¡1 i.p.) further short-
ened the latency (0.95 § 0.14 h, n = 46) compared to vola-
tile anaesthetics (1.21 § 0.39 h,  n =1 7 6 ,   P <0 . 0 0 1 ,
independent sample t test).
Intraperitoneal cisplatin induced a more severe emetic
response and 156 § 41 R+V (n = 19) and 172 (n =6 5 ,  S D
not available) were quantiWed over 4 and 6 h, respectively,
compared to 102 § 52 R+V (n = 180, P < 0.001, indepen-
dent sample t test) and 152 (n = 8, SD not available) fol-
lowing i.v. cisplatin injection (with prior anaesthesia). No
diVerences were observed over an observation period of 2 h
(i.p.: 72 § 41,  n = 22; i.v.: 88 § 32,  n =1 8 ,  P =0 . 1 9 4 ,
independent samples t test). There was not enough data
available on the emetic response quantiWed for 3, 24 and
40 h to investigate the inXuence of the mode of administra-
tion of cisplatin and the use of anaesthesia.
In animals that did not receive any vehicle, the latency
was 1.39 § 0.20 h (n = 18) and ferrets had 92 § 15 R+V
(n =5 ) .  D i Verent vehicles such as saline/distilled water
(1.30 § 0.38 h, n = 296; 97 § 31 R+V, n = 125), propylene
glycol (1.23 § 0.06 h,  n = 4), PEG 300 (1.79 § 0.18 h,
n = 5), Tween 80 (1.22 § 0.19 h, n = 8) and methyl cellu-
lose (1.13 § 0.25 h,  n = 5) impacted on the latency
P < 0.0001, one-way ANOVA) but no signiWcant diVer-
ences were found compared to the group that received
no vehicle (P > 0.05, Bonferroni post-tests). Glucose
(1.33 § 0.24 h,  n =7 ;  1 4 8§ 100 R+V, n =7 )  w a s  a l s o
found to increase the number of R+V (P < 0.05, one-way
ANOVA and Bonferroni post-tests).
No diVerences were detected in latency or number of
R+V over 4 h in groups of male ferrets only compared to
groups of males and females (P > 0.05, independent sample
t tests). The latency was signiWcantly reduced in albino fer-
rets (1.07 § 0.14 h,  n = 29) compared to Wtch ferrets
(1.34 § 0.20 h,  n = 70) and mixed groups of albino and
Wtch ferrets (1.25 § 0.36 h,  n = 108,  P < 0.05, one-way
ANOVA and Bonferroni post-tests) but not enough data
were available to compare the number of R+V.
The latency to the onset of emesis was signiWcantly
longer in ferrets bred in New Zealand (1.73 § 0.37 h,
n = 11) compared to animals bred in the UK (1.25 §
0.44 h, n = 170) and in the USA (1.31 § 0.19 h, n = 176,
P < 0.05, one-way ANOVA and Bonferroni post-tests). No
diVerences were detected in the number of R+V over 4 h
(P > 0.05), but the number of R+V over 2 h was reduced in
New Zealand ferrets (40 § 41 R+V, n = 6) compared to
U.K. animals (88 § 32 R+V, n =1 8 ,  P = 0.007, indepen-
dent sample t tests). As all the ferrets originating from New
Zealand were challenged with an intraperitoneal dose of
cisplatin, a sub-analysis was carried out only in animals
administered cisplatin i.p. and the delay in latency was still
signiWcant in ferrets bred New Zealand compared to ani-
mals bred in the UK (1.43 § 0.46 h, n =2 9 ,  P < 0.05) but
not to animals bred in the USA (1.51 § 0.21 h,  n = 84,
P > 0.05, one-way ANOVA and Bonferroni post-tests).
The 5 mg kg¡1 cisplatin model 
(acute and delayed emesis model)
Fourteen studies investigated cisplatin-induced acute and
delayed emesis in the ferret; cisplatin was administered i.p.
in all studies and no study reported prior use of anaesthesia.
A biphasic proWle of emesis was observed; the acute phase
started 10.51 § 0.58 h (n = 156) after cisplatin administra-
tion, peaked after 12 h and a nadir was reached after 24 h
(Fig. 3b). The delayed phase was more intense than the
acute phase and reached a peak 48 h post cisplatin before
gradually decreasing in intensity during the next 24 h, until
72 h post cisplatin, at which time a small amount of emesis
still persisted. 105 § 83 R+V (n = 215) and 340 § 171
(n = 153) were observed during the acute and delayed
phase, respectively (161 § 98 R+V during day 2 and
179 § 94 R+V during day 3, n = 130). Overall, 448 § 231
R+V (n = 153) were observed during the entire 72-h period.
In animals that did not receive any vehicle, the latency
was 11.76 § 9.86 h (n = 98) and animals that received i.p.
injections of vehicles such as saline, distilled water and
10% NaHCO3 had a latency of 5.52 § 3.32 h (n =1 2 ) ,
8.74 § 8.61 h (n = 41) and 5.71 § 5.66 h (n = 5), respectively.
Fig. 3 ProWle of emesis induced by 10 mg kg¡1 (a)  a n d  5m gk g ¡1 (b)
cisplatin in the ferret. a Data plotted as mean vomits § SD per 30 min
periods, collected from 6 studies involving 34 animals and mean
retches § SD, collected from 4 of those studies involving 20 out of the
34 animals. b Data plotted as weighted mean R+V § SD per 4-h peri-
ods collected from 9 studies involving 92 animals674 Cancer Chemother Pharmacol (2011) 67:667–686
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Overall, the injection of a vehicle had an impact on the
latency (P < 0.0001, one-way ANOVA) but no speciWc
diVerences were detected compared to the group that did
not receive any vehicle (P > 0.05, Bonferroni post-tests).
None of the vehicles had a signiWcant impact on the number
of R+V during the acute or the delayed phase (P >0 . 0 5 ,
one-way ANOVA). Neither the strain nor the sex of the fer-
rets had an impact on the latency or the number of R+V
(P > 0.05, one-way ANOVA).
Meta-analysis: the eVect of anti-emetics
EVect of ondansetron on the acute phase of emesis
Outcome: number of retches and vomits (R+V) Data for
the number of R+V was extracted from 11 full papers, 23
comparisons involving 107 ferrets assessed the eYcacy of
ondansetron versus control during the acute phase of eme-
sis induced by 5 and 10 mg kg¡1 cisplatin. As shown in
Fig. 4, the overall eVect of ondansetron was a reduction of
the R+V by about 70% (¡0.69, ¡0.82 to ¡0.55) and this
was highly signiWcant (Z = 10.05, P < 0.0001). A small sta-
tistical heterogeneity was detected (2 = 37.15,  df =2 3 ,
P =0 . 0 3 ;   I2 =3 8 . 1 % ) .
Five variants of the acute model of cisplatin-induced
emesis were combined in this meta-analysis: emesis
induced by 5 mg kg¡1 cisplatin and R+V quantiWed for
24 h and emesis induced by 10 mg kg¡1 and R+V quanti-
Wed for 24, 6, 4 and 2 h. Ondansetron signiWcantly reduced
the R+V in all variants of the model but one; as shown
Table 3, the reduction of R+V did not reach statistical sig-
niWcance when emesis was induced by 10 mg kg¡1 cis-
platin and quantiWed for 24 h. There was a trend for the
eVect of ondansetron to increase with shorter observation
times (41, 68, 70 and 93% reduction for 24, 6, 4 and 2-h
observation periods, respectively) but this did not reach sta-
tistical signiWcance. The R+V reduction was dose-depen-
dent, doses of 1–10 mg kg¡1 a Vorded a more eVective
protection than lower doses of 0.1–0.5 mg kg¡1 (40 and
83%, respectively, Z =2 . 5 2 ,  P = 0.010). The regimen of
ondansetron administration did not change the outcome; the
eVect of ondansetron was similar with i.v., i.p., and s.c.
injections (Z tests, P > 0.05) and ferrets treated 30 min
prior to cisplatin administration received the same degree
of protection as ferrets treated at the time of cisplatin injec-
tion (Z =0 . 0 4 ,  P = 0.965, see Table 3). With longer obser-
vation periods, ondansetron three times daily was as
eVective as twice-daily injections (Z =0 . 0 5 ,  P =0 . 9 5 9 ) .
Ondansetron had the same eYcacy on the R+V induced by
an i.p. or an i.v. dose of cisplatin (Z =1 . 0 7 ,   P = 0.287) and
the origin of the animals or the quality score of the studies
(see Table 1) did not inXuence the outcome (Z tests,
P >0 . 0 5 ) .
Outcome: number of animals with emesis Data on the num-
ber of animals with emesis was extracted from 14 publica-
tions; 28 comparisons involving 256 ferrets were identiWed.
The global estimate of the eVect of ondansetron was
Fig. 4 EYcacy of ondansetron 
number of retches + vomits 
during the acute phase of emesis 
induced by cisplatin 5 or 
10 mg kg¡1. Point estimates and 
95% conWdence intervals for 
each of the ondansetron versus 
control comparisons ranked by 
dose. The eVect estimate was 
computed as the weighted mean 
diVerence (WMD) and expressed 
as the proportion of retches and 
vomits in the control group. An 
eVect estimate of ¡1 indicates 
that emesis was abolished in the 
treatment group, 0 indicates that 
the treatment had no eVect on the 
R + V response and an eVect 
estimate >0 indicates that the 
treatment increased the number 
of R + V. The size of each 
square represents the weight of 
the comparison in the WMD 
calculationCancer Chemother Pharmacol (2011) 67:667–686 675
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¡0.33 (¡0.48 to 0.17) indicating that following the admin-
istration of cisplatin 5 or 10 mg kg¡1, ondansetron abol-
ished the emetic response during the observation time in
one-third of the ferrets (see Fig. 5). Overall, this eVect was
signiWcant (Z =4 . 0 9 ,   P < 0.001) but a substantial statistical
heterogeneity (2= 115.13, df =2 7 ,  P < 0.001, I2 = 76.5%)
was detected between comparisons. Subgroup analyses
revealed diVerences in estimates of eYcacy between vari-
ants of the model. Whereas ondansetron had a signiWcant
eVect against emesis induced by 10 mg kg¡1 cisplatin and
quantiWed over short observation times (2–4 h) it did not
show any signiWcant eVect against 10 mg kg¡1 cisplatin-
induced emesis quantiWed for 6 and 24 h and 5 mg kg¡1
cisplatin-induced emesis quantiWed for 24 h (see Table 4).
EYcacy increased as the dose increased, and only doses of
ondansetron higher than 0.1 mg kg¡1 had a signiWcant
eVect but there was signiWcant heterogeneity within those
two subgroups (see Table 4). No statistical diVerences were
detected between i.p., i.v. and oral (p.o.) administration of
ondansetron (Z tests, P >0 . 0 5 )  b u t  2 and I2 tests revealed a
high degree of heterogeneity in all 3 subgroups. Adminis-
tered s.c., ondansetron was ineVective but this could
Table 3 Sensitivity analyses of the eVect of ondansetron on the number of retches + vomits (R+V) induced by cisplatin (5 or 10 mg kg¡1)
The eVect estimate was computed as the weighted mean diVerence (WMD) and expressed as the proportion of retches and vomits in the control
group. An eVect estimate of ¡1 indicates that emesis was abolished in the treatment group, 0 indicates that the treatment had no eVect on the R+V
response and an eVect estimate >0 indicates that the treatment increased the number of R+V. The variables examined were the variant of the cis-
platin model (5 or 10 mg kg¡1 cisplatin and the duration of the observation period), the mode of administration of cisplatin, the dose of ondanse-
tron, the regimen of ondansetron administration (mode of delivery and timing relative to cisplatin administration), the animal origin (country
animals were bred) and the quality score assigned to the study where comparisons were extracted
EVect estimate
(proportion of 
R+V diVerence)
95% CI Number of 
comparisons
Overall eVect 
(Z tests)
Heterogeneity 
(2)
Cisplatin dose and duration of the observation period
5 mg/kg (24 h) ¡0.61 ¡0.87 to ¡0.35 5 P < 0.001*** P =0 . 8 0 0
10 mg/kg (24 h) ¡0.41 ¡0.95 to 0.13 4 P =0 . 1 3 P = 0.004**
10 mg/kg (6 h) ¡0.68 ¡1.09 to ¡0.26 3 P = 0.001** P =0 . 1 4 0
10 mg/kg (4 h) ¡0.70 ¡0.94 to ¡0.46 8 P < 0.001*** P =0 . 1 0 0
10 mg/kg (2 h) ¡0.93 ¡1.15 to ¡0.70 4 P < 0.001*** P =0 . 7 5 0
Ondansetron dose
0.01 mg kg¡1 ¡0.71 ¡1.16 to ¡0.26 1 P = 0.002** N/A
0.1–0.5 mg kg¡1 ¡0.40 ¡0.69 to ¡0.10 8 P = 0.009** P =0 . 0 3 0 *
1–10 mg kg¡1 ¡0.83 ¡0.95 to ¡0.70 15 P < 0.001*** P =0 . 6 0 0
Mode of delivery of ondansetron
i.v. ¡0.77 ¡0.95 to ¡0.60 11 P < 0.001*** P =0 . 1 3 0
i.p. ¡0.59 ¡0.81 to ¡0.37 11 P < 0.001*** P =0 . 0 3 0 *
s.c. ¡0.74 ¡1.45 to ¡0.03 2 P =0 . 0 4 0 * P =0 . 7 1 0
Treatment time
With cisplatin ¡0.67 ¡0.86 to ¡0.48 15 P < 0.001*** P =0 . 0 1 0 *
30 min before ¡0.68 ¡1.09 to ¡0.26 3 P = 0.001** P =0 . 1 4 0
Twice daily ¡0.74 ¡1.45 to ¡0.03 4 P =0 . 0 4 * P =0 . 7 1 0
Three times daily ¡0.72 ¡0.98 to ¡0.48 2 P < 0.001*** P =0 . 2 6
Mode of administration of cisplatin
i.v. ¡0.77 ¡0.97 to ¡0.57 9 P < 0.001*** P =0 . 1 0 0
i.p. ¡0.62 ¡0.81 to ¡0.44 15 P < 0.001*** P =0 . 0 8 0
Animal origin
UK ¡0.70 ¡0.88 to ¡0.53 15 P < 0.001*** P =0 . 0 2 0 *
USA ¡0.67 ¡0.91 to ¡0.44 7 P < 0.001*** P =0 . 3 3 0
NZ ¡1.00 ¡0.83 to ¡0.17 1 P =0 . 0 2 0 * N / A
Quality score
Less that 5/9 ¡0.65 ¡0.95 to ¡0.34 5 P < 0.001*** P =0 . 0 6 0
5 to 7/9 ¡0.76 ¡0.97 to ¡0.56 9 P < 0.001*** P =0 . 2 6 0
7.5 to 9/9 ¡0.65 ¡0.88 to ¡0.42 10 P < 0.001*** P =0 . 0 5 0676 Cancer Chemother Pharmacol (2011) 67:667–686
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potentially be misleading as only 2 comparisons were
included in that group and both reported the number of ani-
mals completely protected for 24 h in which setting none of
the animals were completely protected (see Table 4, Fig. 5).
The regimen used did not inXuence signiWcantly the num-
ber of animals completely protected by ondansetron. There
were no diVerences between the subgroup that received
ondansetron at the time of cisplatin injection and the
subgroups that received it 30 min and 1 h prior to cisplatin
(Z tests, P > 0.05) but once again, these results should be
taken with caution as the heterogeneity within each sub-
group was high. With longer observation times (24 h),
ondansetron was equally ineVective given 2 or 3 times a
day. Ondansetron appeared slightly more eVective when
cisplatin was injected i.v. compared to i.p. but this did not
reach statistical signiWcance (Z = 1.757,  P =0 . 0 7 9 )  a n d
could be biased by the fact that in all the comparisons
where animals were observed for 24 h, cisplatin was
injected i.p. Furthermore, heterogeneity was, once again,
highly signiWcant in both groups (see Table 4). The origin
of the animals and the quality score of the studies did not
inXuence the eVect of ondansetron (Z tests, P > 0.05); how-
ever heterogeneity was high in all subgroups (see Table 4).
Outcome: latency Latency data was extracted from 10
full papers. Fifteen comparisons involving 131 ferrets
assessed the eVect of ondansetron on emesis induced by
10 mg kg¡1 cisplatin and 3 comparisons assessed the eVect
of ondansetron on the latency to the onset of emesis
induced by 5 mg kg¡1 cisplatin (see Fig. 6). The global
estimate of the eVect of ondansetron on the latency was
0.86 (0.49–1.24), which means that the latency was nearly
twice as long in the groups treated with ondansetron com-
pared to the control groups. This eVect was signiWcant
(Z =4 . 4 5 ,  P < 0.001) but 2 test revealed a high degree of
heterogeneity (2 =3 1 4 . 3 5 ,   df =1 4 ,  P < 0.001), which was
corroborated by the I2 (96%). Subgroup analysis revealed
that ondansetron statistically delayed the latency to the
onset of emesis induced by 10 mg kg¡1 cisplatin but not
5m gk g ¡1 cisplatin (Table 5, Fig. 6). The eVect of ondanse-
tron was dose dependant and doses of 1 mg kg¡1 conferred
a signiWcantly higher protection, increasing the latency by
about 200% (Z tests, P < 0.05). Ondansetron was more
eVective when given i.p. than p.o. or i.v. (Z tests, P <0 . 0 5 ) ;
however, this result needs to be taken with caution as
ondansetron was injected i.p. in all the comparisons where
the highest dose was given (see Fig. 6). No signiWcant
diVerences were observed with diVerent treatment times,
there was no diVerence in outcome if cisplatin was injected
i.p. or i.v. and the origin of the ferrets did not inXuence the
outcome (Z tests, P > 0.05). The outcome was not
inXuenced by the quality of the study (see Table 1) as no
Fig. 5 EYcacy of ondansetron 
on the number of animals devel-
oping an acute phase of emesis 
following cisplatin 5 or 
10 mg kg¡1. Point estimates and 
95% conWdence intervals for 
each of the ondansetron versus 
control comparisons ranked by 
dose. The eVect estimate was 
computed as the risk diVerence 
(RD) and represents the propor-
tion of animals with emesis dur-
ing the duration of the 
observation period. An eVect 
estimate of 0 indicates that the 
treatment had no eVect on the 
number of animals with emesis, 
¡1 indicates maximal eVect. 
The size of each square repre-
sents the weight of the compari-
son in the total RD calculationCancer Chemother Pharmacol (2011) 67:667–686 677
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diVerences were detected between studies scoring less than
5 out of 9, between 5 and 7/9 and 7.5 or higher (Z tests,
P >0 . 0 5 ) .
Funnel plots for the eVect of ondansetron on the R+V
and the number of animals with emesis were relatively
symmetrical (see Fig. 7). The funnel plot for the latency
was slightly asymmetrical, which reXects the high degree
of heterogeneity detected for this outcome. Overall, no
associations between treatment eVect and sample size were
detected, suggesting no evidence of publication bias.
EVect of 5-HT3 receptor antagonists on the latency 
to the onset of emesis induced by 10 mg kg¡1 cisplatin
The eVects of 5-HT3 receptor antagonists on the latency
to the onset of 10 mg/kg cisplatin-induced emesis were
Table 4 Sensitivity analyses of the eVect of ondansetron on the number of animals with emesis following the administration of cisplatin (5 or
10 mg kg¡1)
The eVect estimate was computed as the risk diVerence (RD) and represents the proportion of animals with emesis during the duration of the obser-
vation period. An eVect estimate of 0 indicates that the treatment had no eVect on the number of animals with emesis, ¡1 indicates maximal eVect.
The variables examined were the variant of the cisplatin model (5 or 10 mg kg¡1 cisplatin and the duration of the observation period), the mode of
administration of cisplatin, the dose of ondansetron, the regimen of ondansetron administration (mode of delivery and timing relative to cisplatin
administration), the animal origin (country animals were bred) and the quality score assigned to the study where comparisons were extracted
EVect estimate
(proportion of 
ferrets with emesis)
95% CI Number of 
comparisons
Overall eVect 
(Z tests)
Heterogeneity 
(2)
Cisplatin dose and duration of the observation period
5 mg/kg (24 h) 0.00 ¡0.15 to 0.15 5 P = 1.000 P =1 . 0 0 0
10 mg/kg (24 h) 0.00 ¡0.23 to 0.23 4 P = 1.000 P =1 . 0 0 0
10 mg/kg (6 h) ¡0.11 ¡0.38 to 0.15 3 P = 0.400 P =0 . 2 8 0
10 mg/kg (4 h) ¡0.48 ¡0.70 to ¡0.26 12 P < 0.001*** P < 0.001***
10 mg/kg (2 h) ¡0.76 ¡1.21 to ¡0.31 4 P = 0.001** P = 0.002**
Ondansetron dose
0.01–0.03 mg kg¡1 ¡0.13 ¡0.37 to 0.12 4 P =0 . 3 1 P =0 . 9 3
0.1–0.5 mg kg¡1 ¡0.39 ¡0.68 to ¡0.11 10 P = 0.006** P < 0.001***
1–10 mg kg¡1 ¡0.33 ¡0.57 to ¡0.10 14 P = 0.006** P < 0.001***
Mode of delivery of ondansetron
i.v. ¡0.49 0.25 to 0.73 12 P < 0.001*** P < 0.001***
i.p. ¡0.14 ¡0.10 to 0.38 11 P =0 . 2 5 P < 0.001***
s.c. ¡0.00 ¡0.27 to 0.27 2 P = 1.000 P =1 . 0 0 0
p.o. ¡0.64 ¡1.16 to ¡0.11 3 P = 0.020* P = 0.020*
Treatment time
With cisplatin ¡0.43 ¡0.68 to ¡0.18 13 P < 0.001*** P < 0.001***
30 min before ¡0.29 ¡0.60 to 0.02 6 P = 0.060 P = 0.020*
1 h before ¡0.64 ¡1.16 to ¡0.11 3 P = 0.020* P = 0.020*
Twice daily 0.00 ¡0.27 to 0.27 2 P = 1.000 P =1 . 0 0 0
Three times daily 0.00 ¡0.16 to 0.16 4 P = 1.000 P =1 . 0 0 0
Mode of administration of cisplatin
i.v. ¡0.49 ¡0.73 to ¡0.25 12 P < 0.001*** P < 0.001***
i.p. ¡0.21 ¡0.41 to ¡0.01 16 P = 0.04* P < 0.001***
Animal origin
UK ¡0.24 ¡0.43 to ¡0.04 14 P = 0.020* P < 0.001***
USA ¡0.36 ¡0.57 to ¡0.14 13 P = 0.001** P < 0.001***
NZ 1.00 ¡1.27 to ¡0.73 1 P < 0.001*** N/A
Quality score
Less that 5/9 ¡0.23 ¡0.62 to 0.16 3 P = 0.250 P = 0.030*
5 to 7/9 ¡0.44 ¡0.66 to ¡0.22 15 P < 0.001*** P < 0.001***
7.5 to 9/9 ¡0.18 ¡0.46 to 0.09 10 P =0 . 1 9 P < 0.001***678 Cancer Chemother Pharmacol (2011) 67:667–686
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investigated with 11 diVerent anti-emetics (ondansetron,
granisetron, tropisetron, indisetron, dolasetron, L-683,877,
renzapride, zacopride, bemesetron, azasetron and ramose-
tron), this data was extracted from 22 studies; 76 compari-
sons were reported, involving 587 ferrets. However, for 14
comparisons, because only one animal developed emesis in
the treatment group, the point estimate and conWdence
interval could not be computed and was therefore not
included in the calculation of the eVect estimate. Alto-
gether, 5-HT3 receptor antagonists increased the latency by
72% (eVect estimate: 0.72, 95% CI 0.56–0.87); this eVect
was highly signiWcant (Z = 9.08,  P < 0.0001) but a high
degree of heterogeneity (2= 1001.57, df =6 1 ,   P < 0.0001,
I2= 93.9%) was detected. Dolasetron (0.02, ¡0.76 to 0.80)
renzapride (1.11, ¡0.18 to 2.40), bemesetron (0.29, ¡0.17
to 120) and ramosetron (0.19, ¡0.02 to 0.39) did not delay
the onset of emesis in a statistically signiWcant manner
(Z tests, P > 0.05), whereas ondansetron (0.88, 0.49–1.27),
granisetron (0.67, 0.41–0.93), tropisetron (0.49, 0.17–0.81),
indisetron (0.92, 0.28–1.57), L-683,877 (0.72, 0.11–1.33),
zacopride (0.79, 0.37–1.20) and azasetron (0.52, 0.37–0.67)
signiWcantly increased the latency by 49–92% (Z tests,
P <0 . 0 5 ) .
EVect of 5-HT3 receptor antagonists on the acute 
and delayed phases of emesis induced by 5 mg kg¡1 cisplatin
Data for the eVects of 5-HT3 receptor antagonists on the
daily emetic response induced by 5 mg kg¡1 i.p. cisplatin
were extracted from 5 studies; 8 comparisons were identi-
Wed, involving 72 animals. 5-HT3 receptor antagonists
reduced the number of R+V by 68% (¡0.68,  ¡0.91 to
¡0.45) on day 1, 67% (¡0.67, ¡0.86 to ¡0.48) on day 2
and 53% (¡0.53, ¡0.85 to ¡0.38) on day 3; this was statis-
tically signiWcant on each of the 3 days (Z =5 . 7 4 ,  Z =6 . 8 1
and Z = 4.44 for day 1, 2 and 3, respectively; P < 0.0001,
see Fig. 8). There was no diVerence between the eVect of
5-HT3 receptor antagonists on each of the 3 days (Z tests,
P > 0.05); no statistical heterogeneity was detected (2
tests,  P > 0.05 and I2= 0% on each of the 3 days). The
eVects of granisetron and ondansetron were signiWcant for
each of the 3 days, whereas indisetron did signiWcantly
reduce the R+V during day 1 and 3 but not day 2. No sig-
niWcant diVerences were detected between the eVects of
ondansetron, granisetron and indisetron for each of the
3d a y s  ( Z tests, P >0 . 0 5 ) .
Discussion and conclusions
Cisplatin-induced emesis in the ferret
We found that the latency to the onset of the cisplatin-
induced emesis was dose dependent, which is consistent
with Wndings in other species such as humans [71], dogs
[10] and pigeons [106]. A step-change was observed
between 5 and 6 mg kg¡1, suggesting a diVerence in
the mechanisms triggering emesis at low and high dose,
Fig. 6 EYcacy of ondansetron on the latency to emesis induced by
cisplatin (5 or 10 mg kg¡1). Point estimates and 95% conWdence inter-
vals for each of the ondansetron versus control comparisons ranked by
dose. The eVect estimate is the impact of the treatment on the latency
expressed as a proportion of the latency in the control group. An eVect
estimate <0 indicates that the latency was shorter in the control group
than in the treatment group, 0 indicates that the treatment had no eVect
on the latency and an eVect estimate of 1 indicates that the treatment
increased the latency by 100%. The size of each square represents the
weight of the comparison in the WMD calculation. Note that in 3 com-
parisons, the eVect estimate was not estimable as only one animal
developed emesis in the group treated with ondansetronCancer Chemother Pharmacol (2011) 67:667–686 679
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possibly the activation of an additional mechanism (e.g.
recruitment of less sensitive vagal aVerent branches, area
postrema). Prior anaesthesia and the route of administration
of cisplatin were identiWed as confounding factors; the
emetic response was also modulated by some of the vehi-
cles used and factors inherent to the ferrets such as strain
and origin. The diVerence between intravenous and intra-
peritoneal cisplatin may only reXect prior anaesthesia, as
these two factors were dependent in the present study.
Certainly, anaesthesia had an impact in its own right as
diVerences were detected between injectable and volatile
anaesthetics. The impact of the ferrets’ origin could reXect
a genuine diVerence between populations of ferrets but it
might also indicate diVerences between laboratories rather
than a diVerence between animals; this cannot be deter-
mined from the present study.
These Wndings however stress the relevance of choosing
appropriate controls (e.g. vehicle control, sham-operated)
and homogeneous groups of animals when using the ferret
cisplatin model of emesis.
Table 5 Sensitivity analyses of the eVect of ondansetron on the latency to the onset of emesis induced by cisplatin (5 or 10 mg kg¡1)
The eVect estimate was computed as the weighted mean diVerence (WMD) and represents the impact of the treatment on the latency expressed as
a proportion of the latency in the control group. An eVect estimate <0 indicates that the latency was shorter in the control group than in the treatment
group, 0 indicates that the treatment had no eVect on the latency and an eVect estimate of 1 indicates that the treatment increased the latency by
100%. The variables examined were the dose and mode of administration of cisplatin, the dose of ondansetron, the regimen of ondansetron admin-
istration (mode of delivery and timing relative to cisplatin administration), the animal origin (country animals were bred) and the quality score
assigned to the study where comparisons were extracted
EVect estimate 
(proportion of 
latency change)
95% CI Number of 
comparisons
Overall eVect 
(Z tests)
Heterogeneity 
(2)
Cisplatin dose
10 mg kg¡1 0.88 0.49 to 1.27 15 P < 0.001*** P < 0.001***
5m gk g ¡1 0.60 ¡0.97 to 2.16 3 P =0 . 4 5 P =0 . 2 9
Ondansetron dose
0.01–0.02 mg kg¡1 0.36 0.00 to 0.72 3 P =0 . 0 5 0 P = 0.008**
0.03–0.06 mg kg¡1 0.85 0.30 to 1.40 3 P = 0.002** P < 0.001***
0 . 1m gk g ¡1 0.49 0.31 to 0.67 5 P < 0.001*** P =0 . 1 4 0
1m gk g ¡1 1.96 1.66 to 2.25 7 P < 0.001*** P =0 . 2 7
Mode of delivery of ondansetron
i.v. 0.60 0.35 to 0.85 9 P < 0.001*** P < 0.001***
p.o. 0.34 0.15 to 0.53 2 P < 0.001*** N/A
i.p. 1.54 0.67 to 2.41 5 P < 0.001*** P < 0.001***
s.c. 0.36 ¡0.94 to 1.65 2 P =0 . 5 9 P =0 . 3 1
Treatment time
With cisplatin 0.62 0.34 to 0.68 6 P < 0.001*** P = 0.010*
20–30 min before 1.11 0.25 to 1.96 5 P = 0.010** P < 0.001***
1 h before 0.34 0.15 to 0.53 2 P = 0.010** N/A
30 min before and 45 min after 0.94 ¡0.01 to 1.89 2 P =0 . 0 5 0 * P < 0.001***
Twice daily 0.36 ¡0.94 to 1.65 2 P =0 . 5 9 0 P =0 . 3 1 0
Three times daily 5.83 ¡3.02 to 14.68 1 P =0 . 0 2 0 * N / A
Mode of administration of cisplatin
i.v. 0.60 0.35 to 0.85 9 P < 0.001*** P < 0.001***
i.p. 1.16 0.35 to 1.96 9 P =0 . 0 0 5 P < 0.001***
Animal origin
UK 0.76 0.44 to 1.07 5 P < 0.001*** P =0 . 1 9
USA 0.86 0.39 to 1.33 13 P < 0.001*** P < 0.001***
Quality score
Less that 5/9 0.94 ¡0.01 to 1.89 2 P =0 . 0 5 0 P < 0.001***
5 to 7/9 0.63 0.32 to 0.94 11 P < 0.001*** P < 0.001***
7.5 to 9/9 1.42 0.31 to 2.53 5 P =0 . 0 1 * * P < 0.001***680 Cancer Chemother Pharmacol (2011) 67:667–686
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The proWle of emesis induced by 5 mg kg¡1 i.p. cisplatin
in the ferret was clearly biphasic, which is consistent with
the proWle of emesis observed in the clinic [84] but diVer-
ences were observed in the timing and magnitude of the two
phases. Whereas the acute phase is more severe than the
delayed phase in humans [72, 84], with an onset 1–6 h fol-
lowing cisplatin infusion [55,  71,  84], the latency to the
onset of the acute phase was greater in the ferret (>10 h) and
its relative intensity compared to the delayed phase was
lower. The incidence of emesis on each day could not be
investigated in the ferret as all reports stated that 100% of
the animals developed an emetic response but no distinction
was made between the acute and delayed phases. A few
studies have however suggested that the acute phase was not
observed in all animals [115, 147], which is also consistent
with our recent observations [104] and suggests that whereas
the incidence of emesis during the delayed phase is close to
100%, the incidence of acute emesis at this dose is lower. In
humans treated with placebo anti-emetics, however, the inci-
dence of emesis during the acute phase (98%, [71]) is higher
than during the delayed phase (44–89% [43, 72]).
EVect of 5-HT3 receptor antagonists
The eYcacy of ondansetron in the acute model of cisplatin-
induced emesis was assessed measuring 3 outcomes: the
Fig. 8 EYcacy of 5-HT3 recep-
tor antagonists on the daily num-
ber of retches + vomits (R + V) 
induced by 5 mg kg¡1 i.p. cis-
platin during the acute (day 1) 
and delayed (days 2, 3) phases of 
emesis. Point estimates and 95% 
conWdence intervals for each of 
the 5-HT3 receptor antagonist 
versus control comparisons 
ranked by dose. The eVect esti-
mate was computed as the 
weighted mean diVerence 
(WMD) and expressed as the 
proportion of retches and vomits 
in the control group. An eVect 
estimate of ¡1 indicates that 
emesis was abolished in the 
treatment group, 0 indicates that 
the treatment had no eVect on the 
R + V response and an eVect 
estimate >0 indicates that the 
treatment increased the number 
of R + V. The size of each 
square represents the weight of 
the comparison in the WMD cal-
culation
Fig. 7 Funnel plots for the eVect of ondansetron on the number of
retches + vomits (a), number of animals with emesis (b) and latency
(c). For each comparison, the eVect estimates are plotted on the x-axis
and corresponding standard errors are plotted on the y-axisCancer Chemother Pharmacol (2011) 67:667–686 681
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number of R+V, the number of animals with emesis and the
latency to the onset of emesis. Overall, all 3 outcomes per-
mitted the detection of signiWcant anti-emetic protection,
which is consistent with Wndings in humans [24], but diVer-
ent variants of the model resulted in diVerent levels of anti-
emetic protection. Whereas all variants of the acute model
reXected a similar reduction of R+V, ondansetron only
delayed signiWcantly the onset of emesis following 10 but
n o t  5m gk g ¡1 cisplatin, and the number of animals with
emesis was only reduced with observation periods no
longer than 4 h. In the 10 mg kg¡1 4 h variant of the model,
half of the animals were completely protected from emesis,
which was comparable to percentage of patients free of
emesis during the acute phase of high-dose (>50 mg m¡2)
cisplatin-induced emesis in human patients [58,  65,  85,
124]. Overall, the acute phase of emesis induced by
5m gk g ¡1 cisplatin represented poorly the clinical situation
and the 4 h to 10 mg kg¡1 model was more predictive of
cisplatin-induced emesis in humans.
Overall, 5-HT3 receptor antagonists reduced the emetic
response to the same extent during the acute and delayed
phases, which contrasts with Wndings reported in the major-
ity of clinical studies, describing limited or non-signiWcant
eVect of 5-HT3 receptor antagonists during the delayed
phase [57, 73]. This discrepancy may be explained by a
diVerence in outcome usually measured in humans (daily
incidence, percentage of patients developing emesis) and
ferrets (severity, number of R+V). Even though daily inci-
dence and severity (measured by visual analogue scale) of
the delayed phase emesis appear to be positively correlated
in the absence of anti-emetic therapy [72], they can be
uncoupled following anti-emetic treatment and the number
of emetic episodes may be reduced while the incidence
remains unchanged [100]. Alternatively, it is conceivable
that the delayed phase of emesis in the ferret is more sensi-
tive to 5-HT3 receptor antagonists than it is in humans. The
latter would be consistent with a longer acute phase in the
ferret (see [110] for details), implying that the mechanism
regulating the acute phase (i.e. 5-HT-mediated activation of
the abdominal vagal aVerents) remains activated longer.
The ferret model thus correctly identiWed the anti-emetic
potential of 5-HT3 receptor antagonists against both the
acute and delayed phases of cisplatin-induced emesis, but
the magnitude of the anti-emetic eVect during the delayed
phase appears greater in the ferret than it is in humans.
Methodology
In the present study, the methodology used in the meta-
analysis of human clinical trials was modiWed and adapted
to animal research, and several concessions had to be made.
First of all, the criteria used to select studies for inclusion
into the systematic review and meta-analysis, and assess
quality, did not include randomization and blinding.
Whereas these two parameters are considered essential for
human clinical trials and it has been suggested that their
absence favours positive Wndings in animal research [8],
emesis is an objective measurement, which is not investiga-
tor-dependent and we have no reason to believe that the
inclusion of such studies in our analysis biased our Wnd-
ings. Additionally, randomization and blinding in the iden-
tiWed studies were too rarely reported to be used as
inclusion criteria. The exclusion criteria were chosen to
ensure the collection of reliable, clearly deWned data. The
majority of excluded studies (see Table 2) were removed
because emesis was not quantiWed as latency, retches,
vomits and/or incidence. We chose not to include outcomes
such as “emetic episodes” or “bouts of emesis” in the
present analysis because of the disparity of deWnitions and
possible interpretations. This may however restrict the
conclusions of our study.
Secondly, whereas clinical trials usually report tens or
hundreds of patients in each study arm, we found that in the
cisplatin ferret model, typically 4 to 8 animals were allo-
cated in each treatment group. This may limit the relevance
of such an analysis, designed to compare much bigger sam-
ples. Additionally, because a majority of studies compared
one control group to several treatment groups—typically
diVerent doses of a compound—in order to maintain the
data from diVerent doses as distinct comparisons, the num-
ber of animals in the control group was divided by the num-
ber of treatment groups it was compared to. The limitation
of such an approach is that in the eVect estimate calcula-
tion, the weight of such comparisons is reduced, which
beneWts comparisons extracted from studies that only com-
pared one control group to one treatment group and is not
justiWed by the quality of the studies.
Conclusions
We demonstrated the potential of a meta-analysis to
address the 3R’s (Replacement, ReWnement and Reduc-
tion), developed by Russel and Burch as criteria for a
humane use of animals in research [126]. By maximising
the utilisation of animal data, thus extracting novel scien-
tiWc information without increasing the number of animals,
such analysis addresses Reduction, as this reduces the
future use of animals. Additionally, the eVects of ondanse-
tron on the 3 outcomes highlighted a logical ReWnement of
the model by reducing the observation period. The cisplatin
10 mg/kg to 4 h variant of the model stands out as the most
appropriate to study the acute phase of cisplatin-induced
emesis, whereas 5 mg/kg to 24–72 h remains the model of
choice to study cisplatin-induced delayed emesis.
The present study is a proof of concept. In an attempt to
focus the scope of the analysis, it was limited to an animal682 Cancer Chemother Pharmacol (2011) 67:667–686
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model with one emetic: cisplatin, one species: the ferret and
one class of anti-emetic drugs: 5-HT3 receptor antagonists;
the drugs investigated are already successfully used in
humans against chemotherapy-induced emesis. Globally, the
eVects in the ferret were consistent with clinical Wndings,
which were expected as they were originally developed in
the ferret model; this demonstrates that a meta-analysis is an
appropriate method to identify the anti-emetic potential of a
drug and conWrms that the ferret model of cisplatin-induced
emesis is truly predictive and relevant to humans. This
method can now be applied to investigate the eVects of NK1
receptor antagonists, which were also developed using
the ferret and which have recently been introduced into the
clinic. However, recent studies suggest that there may be
a discrepancy between the “broad spectrum” anti-emetic
eYcacy in the ferret and the eYcacy in the clinic [3, 25].
This method can also be used in other “model” species (e.g.
dog) to reassess “older” compounds such as dopamine
receptor antagonists or opioids, whose eVects on cisplatin-
induced emesis are less well characterised. It can also be
directly applied to other emetic models (diVerent emetogen
and/or diVerent species) and adapted to assess the relevance
of models arguably predictive of nausea and emesis such as
pica in the rat and conditioned taste aversion [2, 77].
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